Vanessa C. Vaughan

Vanessa C. Vaughan

Auto-generated profile, based on publicly available information

Vanessa C. Vaughan

School of Medicine, Deakin University, Waurn Ponds, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2012 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
VVVanessa C. Vaughan
Vanessa C. Vaughan
PMPeter Martin
Peter Martin
PLPaul Lewandowski
Paul Lewandowski
Many forms of cancer present with a complex metabolic profile characterised by loss of lean body mass known as cancer cachexia. The physical impact of cachexia contributes to decreased patient quality of life, treatment success and survival due to gross alterations in protein metabolism, increased oxidative stress and systemic inflammation. The psychological impact also contributes to decreased quality of life for both patients and their families. Combination therapies that target multiple pathways, such as eicosapentaenoic acid administered in combination with exercise, appetite stimulants, antioxidants or anti‐inflammatories, have potential in the treatment of this complex syndrome and require further development.

8 January 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
VVV C Vaughan
V C Vaughan
MHM-R Hassing
M-R Hassing
PLPaul Lewandowski
Paul Lewandowski
Polyunsaturated fatty acids (PUFAs) derived from marine sources, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are widely consumed as supplements within the community. However, the use of marine PUFAs in a therapeutic context is also increasing in patients receiving treatment for a range of cancer types. On balance, the literature suggests that marine PUFAs have potential as an effective adjuvant to chemotherapy treatment, may have direct anticancer effects, and may help ameliorate some of the secondary complications associated with cancer. Although a range of doses have been trialled, it would appear that supplementation of fish oil (>3 g per day) or EPA/DHA (>1 g EPA and >0.8 g DHA per day) is associated with positive clinical outcomes. However, further research is still required to determine the mechanisms via which marine PUFAs are mediating their effects. This review summarises our current understanding of marine PUFAs and cancer therapy.

13 September 2013 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
EHE. C. A. Hinch
E. C. A. Hinch
MSM. J. Sullivan-Gunn
M. J. Sullivan-Gunn
VVV. C. Vaughan
V. C. Vaughan
MMM. A. McGlynn
M. A. McGlynn
PLPaul Lewandowski
Paul Lewandowski
Background: Current research into the mechanisms of organ atrophy associated with cancer cachexia have centred on the loss of skeletal muscle, as it is one of the most profound physical changes of the disease. However, many patients with cancer cachexia also experience significant atrophy of the heart. The mechanisms causing cardiac tissue wastage in cancer cachexia are largely unknown. However, it is believed to involve a number of molecular interactions between the tumour and host. Increased levels of oxidative stress have been found in cancer cachectic skeletal muscle and has been linked to the activation of the ubiquitin proteosome system (UPS). The aim of the current study was to examine the role of oxidative stress and the UPS in the hearts of mice with cancer cachexia.Methods: Oxidative damage to DNA (8‐OH‐2dG), mRNA levels of the ROS‐producing enzymes NADPH oxidase (NOX), and xanthine oxidase (XDH), the antioxidant enzyme superoxide dismutase (SOD) and key components of the UPS was measured in the heart of mice with cancer cachexia. Protein expression levels of NOX enzyme subunits and SOD enzyme activity was also measured in the same heart samples.Results: 8‐OH‐2dG levels were 1.5‐fold higher in the heart of mice with cancer cachexia, and this was associated with a 1.7‐fold lower level of NOX2 mRNA and twofold higher XDH mRNA in the same hearts. Cancer cachexia was also associated with a 1.5‐fold lower level of SOD activity in the heart. Accompanying these pro‐ and antioxidant differences was a significantly higher level of mRNA for the key UPS elements MURF‐1 (4.3=fold) and MAFbx (3.8‐fold) in the hearts of mice with cancer cachexia.Conclusions: The current study demonstrated that cardiac atrophy of cachectic mice is associated with oxidative damage to DNA in the myocardium. The higher levels of XDH mRNA in cachectic hearts suggest that xanthine oxidase may have an important role to play in producing oxidative stress. It appears that the combination of higher XDH expression and lower SOD enzyme activity are key contributors to oxidative stress and cardiac tissue damage in cancer‐induced cardiac atrophy. Oxidative stress in the myocardium as with skeletal muscle may also induce increased expression of the E3 ligases MURF‐1 and MAFbx as seen in this study.Electronic supplementary material: The online version of this article (doi:10.1007/s13539‐013‐0116‐8) contains supplementary material.

1 March 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
MSM Sullivan-Gunn
M Sullivan-Gunn
EHE Hinch
E Hinch
VVV Vaughan
V Vaughan
PLPaul Lewandowski
Paul Lewandowski
Choosing a stable housekeeping gene and protein is essential in generating valid gene and protein expression results

2 October 2019 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
VVVanessa C Vaughan
Vanessa C Vaughan
HFHelen Farrell
Helen Farrell
PLPaul A Lewandowski
Paul A Lewandowski
SMScott G McCoombe
Scott G McCoombe
PMPeter Martin
Peter Martin

20 September 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VVVanessa C. Vaughan
Vanessa C. Vaughan
MSMelanie Sullivan-Gunn
Melanie Sullivan-Gunn
EHEdward Hinch
Edward Hinch
PMPeter Martin
Peter Martin
PLPaul Lewandowski
Paul Lewandowski
Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with cancer cachexia were randomized into 4 treatment groups (EPA (0.4 g/kg/day), oxypurinol (1 mmol/L ad-lib), combination, or control), and euthanized after 29 days. Analysis of oxidative damage to DNA, mRNA analysis of pro-oxidant, antioxidant and proteolytic pathway components, along with enzyme activity of pro- and antioxidants were completed on gastrocnemius muscle. The control group displayed earlier onset of tumor compared to EPA and oxypurinol groups (P<0.001). The EPA group maintained body weight for an extended duration (20 days) compared to the oxypurinol (5 days) and combination (8 days) groups (P<0.05). EPA (18.2±3.2 pg/ml) and combination (18.4±3.7 pg/ml) groups had significantly higher 8-OH-dG levels than the control group (12.9±1.4 pg/ml, P≤0.05) indicating increased oxidative damage to DNA. mRNA levels of GPx1, MURF1 and MAFbx were higher following EPA treatment compared to control (P≤0.05). Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to control (P≤0.05). Activity of total SOD was higher in the oxypurinol group (32.2±1.5 U/ml) compared to control (27.0±1.3 U/ml, P<0.01), GPx activity was lower in the EPA group (8.76±2.0 U/ml) compared to control (14.0±1.9 U/ml, P<0.05), and catalase activity was lower in the combination group (14.4±2.8 U/ml) compared to control (20.9±2.0 U/ml, P<0.01). There was no change in XO activity. The increased rate of weight decline in mice treated with oxypurinol indicates that XO may play a protective role during the progression of cancer cachexia, and its inhibition is detrimental to outcomes. In combination with EPA, there was little significant improvement from control, indicating oxypurinol is unlikely to be a viable treatment compound in cancer cachexia.